Sunshine Biopharma, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| SBFMW | BIIB | SNGX | SNY | JSPR | BHVN | |
|---|---|---|---|---|---|---|
| Market cap | — | 34.66B | 7.47M | 95.73B | 15.97M | 1.71B |
| P/E (TTM) | — | 41.7 | — | 21.0 | — | — |
| Forward P/E | — | 14.2 | -1.4 | 7.6 | -0.7 | -6.1 |
| Price/book | 0.0 | 1.8 | 1.1 | 1.2 | 9.6 | 139.9 |
| Dividend yield | — | — | — | 5.96% | — | — |
| 1-year change | — | +58.66% | −79.41% | −18.34% | −80.88% | −38.54% |
| Today | 0.00% | +0.83% | −2.86% | −1.63% | −9.81% | +5.15% |
The closest companies by business. Prices may be delayed up to 15 min.
Latest news
All SBFMW news ›Sunshine Biopharma approves discounted warrant issuance
The Series D warrant ownership blocker is 4.99%, with holder elections allowed up to 9.99% and increases delayed 61 days. Sunshine Biopharma Inc. (SBFM) obtained written consent approving Series D warrant provisions. Chief Executive…
Sunshine Biopharma approves issuance exceeding 20%
QTREX Quantum Announces Clean Capital Structure The consent also covers specified adjustments to Series D Warrants and takes effect 20 days after the definitive information statement is mailed. Sunshine Biopharma Inc. (SBFM) says CEO Dr.…
Sunshine Biopharma: BJI Financial Group has 6% voting power
A financial group reports voting power over 909,900 Sunshine Biopharma (SBFM) shares. Stock Titan - [SCHEDULE 13G] Sunshine Biopharma Inc. Passive Investment Disclosure (>5%) Sunshine Biopharma: BJI Financial Group has 6% voting power The…
Sunshine Biopharma: CVI reports a 9.9% stake
909,090 shares plus warrants underpin a reported stake in Sunshine Biopharma (SBFM). Stock Titan - [SCHEDULE 13G] Sunshine Biopharma Inc. Passive Investment Disclosure (>5%) Sunshine Biopharma: CVI reports a 9.9% stake Sentiment and the…
Sunshine Biopharma secures Canadian approval for generic Enalapril
Sunshine Biopharma Inc. (NASDAQ: SBFM) secured regulatory approval for generic Enalapril tablets in Canada, available in 2.5mg, 5mg, 10mg, and 20mg strengths. The company plans to distribute the drug via its subsidiary Nora Pharma, with…
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Sees Significant Growth in Short Interest
Sunshine Biopharma, Inc. (NASDAQ:SBFM – Get Free Report) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totaling 131,478 shares, an increase of 461.6% from the…
Sunshine Biopharma Completes $6 Million Public Offering
Sunshine Biopharma ( (SBFM) ) has provided an update. Spark’s Take on SBFM Stock According to Spark, TipRanks’ AI Analyst, SBFM is a Neutral. More about Sunshine Biopharma Current Market Cap: $3.02M For detailed information about SBFM…
Sunshine Biopharma Announces Closing of up to $20.4 Million Public Offering
$6.0 million upfront with an additional $14.4 million of potential aggregate gross proceeds upon the exercise of warrants Gross proceeds to the Company were approximately $6.0 million. The potential additional gross proceeds to the Company…
Sunshine Biopharma announces pricing of $6M public offering
Sunshine Biopharma (SBFM) priced a $6M public offering at $0.55/unit with Series D warrants, closing Oct. 9. - Sunshine Biopharma (SBFM) on Thursday announced the pricing of a public offering made on a reasonable best efforts basis with…
SBFM Stock Pops As Sunshine Biopharma Pushes Antiviral, Generics
Sunshine Biopharma Inc. stocks have been trading up by 47.13 percent amid heightened optimism surrounding its latest biotech developments. SBFM has been trading like a classic low-priced biotech with a news catalyst. In the multi-day…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net6
-
digitaljournal.com2
-
defenseworld.net1
-
scanx.trade1
-
seekingalpha.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 15 articles, not a forecast.